3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Pancreatic Neoplasms
2
Sarcoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Melanoma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
Nivolumab
21
pembrolizumab
19
Ipilimumab
14
Specimen Handling
12
Magnetic Resonance Spectroscopy
7
Opdualag
6
CTLA-4 Antigen
6
relatlimab
5
binimetinib
5
trametinib
4
Paclitaxel
4
dabrafenib
3
Taxes
3
Standard of Care
3
Pemetrexed
3
Introns
3
Interferon alpha-2
3
Gemcitabine
3
Carboplatin
3
Blood Specimen Collection
3
ulixertinib
2
sargramostim
2
lifileucel
2
lenvatinib
2
fludarabine phosphate
2
fludarabine
2
encorafenib
2
capivasertib
2
cabozantinib
2
atezolizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
Genetic Counseling
×
30 days
×
Clear all
NCT05225428
2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA
Recruiting
1,020 enrolled